Glonghui, March 16, 丨 Morgan Stanley published a report saying that according to Tongrentang Sinopharm's performance in the second half of fiscal year 2022, its profit forecast for 2023 to 2030 was raised by 8 to 10%. Higher sales are expected to offset the impact of lower gross margin and indicate that the company's working capital has improved. The bank raised the target price of Tongrentang Sinopharm from HK$14.2 to HK$16, which is equivalent to predicting a price-earnings ratio of 8 times this year. The rating is “increase in holdings.”